Global Phase I Capacity Celerion operates a broad Phase I footprint with multiple locations and substantial bed capacity, enabling rapid patient enrollment and diverse population representation for Phase I trials. This combination helps sponsors accelerate feasibility assessments and shorten study timelines.

Cardiovascular Expertise Strong cardiovascular safety capabilities including targeted early human studies and a new senior cardiology appointment position Celerion as a go to partner for cardio focused programs and NDA enabling data.

Integrated Platform An integrated translational platform spanning PK PD modeling, biostatistics, regulatory support, medical writing, and Labnotes bioanalytical data management delivers end to end data solutions. This enables faster decisions and streamlined trial workflows.

Global Expansion ESG Strategic expansion and sustainability initiatives signal a globally scalable and ESG conscious partner for multinational trials. Engage sponsors prioritizing global execution regulatory alignment and science based emissions targets.

Growth Credibility Industry recognition, ongoing growth funding, and a strong revenue base underpin Celerion's credibility and capacity to scale with large pharma and biotech programs. Position this as a reliable long term partner to support portfolio diversification and complex early stage needs.